|
|
News Breaks | | | | March 6, 2013 | | 07:02 EDT |  | SNTS | Santarus, VeroScience announce publication of recommendations for CYCLOSET
Santarus and VeroScience announced publication of a review article and recommendations of an American Association of Clinical Endocrinologists expert panel on the role of bromocriptine-QR in the management of type 2 diabetes. The panel concluded that treatment with CYCLOSET, also referred to as bromocriptine-QR, may be useful in the treatment of patients with type 2 diabetes, both early and late in the life cycle of the disease, and especially for patients with a history of cardiovascular disease or who have significant risk factors for cardiovascular disease. The article, titled The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations will appear in print form in the January/February issue of Endocrine Practice, a peer-reviewed medical journal published by AACE. | |
|
News For SNTS From The Last 14 Days Check below for free stories on SNTS the last two weeks. |
|
|
| May 24, 2013 | | 11:23 EDT |  | SNTS | High option volume stocks: SNTS XHB EWH MCK MAN
 Subscribe for More Information | | | May 17, 2013 | | 10:36 EDT |  | SNTS | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | |
|
|
|
|
|
|
